ARS Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-54.37	-34.68	-20.24	-32.95	-23.97	-17.58
Depreciation & Amortization	0.07	0.03	0.21	1.71	1.55	1.42
Share-Based Compensation	9.24	5.84	2.83	2.64	0.15	0.29
Other Operating Activities	-14.21	-11.27	-0.36	-2.6	3.38	-1.01
Operating Cash Flow	-59.27	-40.08	-17.56	-31.2	-18.9	-16.88
Capital Expenditures	-0.18	-0.2	-0.06	-0.92	-0.1	-0.45
Change in Investments	-87.01	0	0	0	0	0
Investing Cash Flow	-87.18	-0.2	-0.06	-0.92	-0.1	-0.45
Share Issuance / Repurchase	6.9	0.57	0.17	258.46	0.02	0.28
Debt Issued / Paid	0	-8.68	-1.82	-0.7	8.59	-0.85
Other Financing Activities	-	198.84	54.81	150.75	-	19.97
Financing Cash Flow	6.9	190.73	53.16	408.51	8.61	19.4
Net Cash Flow	-139.55	150.46	35.54	376.39	-10.38	2.08
Free Cash Flow	-59.44	-40.28	-17.62	-32.11	-18.99	-17.32
Free Cash Flow Margin	-198136.67%	-3060.56%	-319.94%	-	-	-
Free Cash Flow Per Share	-0.62	-1.01	-0.61	-11.04	-28.74	-28.69

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).